Dyadic announced an mou with bangladesh's state-owned pharmaceutical company to facilitate biopharmaceutical research and biomanufacturing capacity

Jupiter, fla. and dhaka, bangladesh, june 21, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it has entered into a memorandum of understanding (“mou”) with essential drugs company limited (edcl), the state owned pharmaceutical company under the ministry of health and family welfare of bangladesh to facilitate biopharmaceutical research, pre-clinical development, cgmp production, clinical trials, regulatory and other relevant areas of interest in bangladesh.
DYAI Ratings Summary
DYAI Quant Ranking